滇港澳共拓“云药”出海新路 生物医药产业加速国际化

Core Insights - In 2024, Yunnan's biopharmaceutical industry is projected to achieve a revenue exceeding 320 billion yuan, indicating both quantitative growth and qualitative improvement [2] - The Yunnan government aims to enhance cooperation with Hong Kong and Macau in biomanufacturing and modern traditional Chinese medicine, exploring mutually beneficial development models [2] - The 2025 Yunnan-Hong Kong-Macau Entrepreneurs Forum focused on the internationalization of Yunnan's traditional medicine, with representatives discussing collaboration across the entire industry chain [2] Industry Development - Yunnan is recognized as a "plant kingdom" and "medicinal herb hometown," boasting rich biological and ethnic medicinal resources, making it the largest producer of traditional Chinese medicine in China [2] - The province has established a biopharmaceutical research and production system centered on vaccines, alongside a comprehensive development system for natural medicines, including traditional Chinese medicine and health products [2] Collaborative Opportunities - Future cooperation between Yunnan, Hong Kong, and Macau can deepen in areas such as academic exchange, diagnostic technology training, enterprise collaboration, and new drug development [3] - The collaboration is timely, with potential in seed industry innovation, digital synergy, and cooperative mechanisms to activate Yunnan's resource potential while leveraging Hong Kong and Macau's platforms for global outreach [3] - Macau's pharmaceutical industry can assist in promoting traditional Chinese medicine products to Portuguese-speaking countries and ASEAN regions, focusing on standardization, product development, quality certification, and brand building [3]